Trius Therapeutics' Series B Round

Trius Therapeutics raised a round of funding on March 14, 2008.

Trius Therapeutics is discovering and developing antibacterial drugs for the treatment of life-threatening infections. The company's lead product candidate, TR-701 is a oral and IV oxazolidinone antib…

Articles about Trius Therapeutics' Series B Round: